Journal of Carcinogenesis
Covering Genesis to Therapeutics

Journal of Carcinogenesis, ISSN: 1477-3163
2025; Vol 24: Issue 9s, https://carcinogenesis.com/

A Review On: Force Degradation Studies & Stability Indicating RP-HPLC Methods for Selected Antiemetic Drug

Manish Bhise[1], Ashish Gawai[2], Shailesh Bharad[3], Shivanand Wagh[4], Amol Rakte[5], Mohd Hasib Ahmed[6], Nitin Gawai*[7], Taufik Mulla[8]

[1]S.G.S.P.S Institute of Pharmacy, Akola, M.S., India.

[2]Rajarshi Shahu College of Pharmacy, Buldana, M.S., India.

[3]Satpuda Institute of Pharmacy, Shegaon, Dist-Buldana, M.S., India.

[4]Mahadev Kanchan College of Pharmaceutical Education and Research Uruli Kanchan, Pune , M.S., India.

[5]IVMs Krishnarao Bhegade Institute of Pharmaceutical Education and Research, Talegaon Dabhade, Tal-Maval, Dist-Pune, M.S., India.

[6]Karmayogi Tatyasaheb Bondre Institute of Pharmacy, Chikhli, Dist-Buldana, M.S., India.

[7]Mahadev Kanchan College of Pharmaceutical Research, Urali Kanchan, Tal-Haveli, Dist-Pune, M.S., India.

[8]Institute of Pharmaceutical Sciences, Faculty of Pharmacy, Parul University, P.O. Limda, Tal. Waghodia - 391760, Dist. Vadodara, Gujarat, India.

Corresponding Author: Nitin Motiram Gawai, Principal, Mahadev Kanchan College of Pharmaceutical Research, Urali Kanchan, Tal-Haveli, Dist-Pune, M.S., India.

Email ID- nitin.gawai@gmail.com

Orcid ID-0009-0001-7849-8983

ABSTRACT

The development of analytical procedures that indicate stability is crucial for pharmaceutical goods because it ensures their quality, safety, and effectiveness throughout their shelf life. Because of its great sensitivity, repeatability, and capacity to resolve complicated mixtures, reverse-phase high-performance liquid chromatography (RP-HPLC) has become the most used analytical technique.Antiemetic drugs such as hyoscine N-butyl bromide (HBB), promethazine hydrochloride, and paracetamol—often used in combination with antiemetics—require robust analytical procedures to monitor degradation pathways and assess stability under stress conditions. Force degradation studies, including hydrolytic, oxidative, photolytic, and thermal stress testing, are essential in evaluating the stability profile of these drugs and in establishing reliable stability-indicating methods in accordance with ICH guidelines.Development and validation of RP-HPLC techniques for specific antiemetic medicines are now subject to regulatory restrictions and recommendations, which this paper comprehensively summarizes. The significance of forced degradation research in specificity testing, product identification, and degradation mechanism elucidation is highlighted. In addition, the study emphasizes the use of RP-HPLC technologies for regular analysis of pharmaceutical formulations and bulk medicines, quality control, and pharmacokinetic estimates. This review seeks to optimize stability-indicating RP-HPLC methods for antiemetic agents by combining recent advances and regulatory perspectives. The ultimate goal is to improve therapeutic reliability and comply with global regulatory standards.

Keywords: *RP-HPLC, antiemetic, Force Degradation Studies & Stability*

How to Cite: Manish Bhise, Ashish Gawai, Shailesh Bharad, Shivanand Wagh, Amol Rakte, Mohd Hasib Ahmed, Nitin Gawai, Taufik Mulla, (2025) A Review On: Force Degradation Studies & Stability Indicating RP-HPLC Methods for Selected Antiemetic Drug, *Journal of Carcinogenesis*, *Vol.24, No.9s*, 284-291.

1. INTRODUCTION

Antiemetic drugs play a crucial role in the management of nausea and vomiting associated with various conditions such as chemotherapy, surgery, gastrointestinal disorders, and motion sickness. Ensuring the quality, safety, and efficacy of these drugs throughout their shelf life requires the development of robust analytical methods that can accurately determine their stability and detect degradation products. Among the various analytical tools,RP-HPLC) has emerged as the most widely employed technique due to its high sensitivity, accuracy, reproducibility, and versatility in analyzing both bulk drugs and pharmaceutical formulations. [1-2]

Stability-indicating methods (SIMs) are particularly important in pharmaceutical analysis as they can distinguish between the intact drug and its degradation products formed under stress conditions such as hydrolysis, oxidation, photolysis, and thermal degradation. Force degradation studies, as recommended by regulatory agencies like the International Council for Harmonisation (ICH), provide essential insights into the degradation pathways and intrinsic stability of drug molecules. Such studies are indispensable for establishing drug shelf life, recommending suitable storage conditions, and designing formulations with enhanced stability. [3-4]

(HBB, promethazine hydrochloride, and paracetamol are commonly used antiemetic and adjunctive agents that have been extensively studied for their stability and degradation behavior. A comprehensive understanding of their chromatographic evaluation is necessary for accurate quality control and pharmacokinetic assessment. This review focuses on the regulatory requirements, methodological aspects, and recent advances in the development and validation of stability-indicating RP-HPLC methods for selected antiemetic drugs, with an emphasis on their role in pharmaceutical research and clinical applications. [5-6]

2. HISTOLOGICALBACKGROUND

The need for systematic stability testing in pharmaceuticals was first highlighted during a regional workshop on the validation of drug expiry dates held in Amman, Jordan. This workshop emphasized the importance of drug stability and expiry dates and urged collaboration between medical authorities and pharmaceutical companies to establish standardized practices. In response, the U.S. Food and Drug Administration (FDA) issued its first stability guidance in 1987.Subsequently, considerable efforts were directed towards harmonizing stability testing practices across different regions, leading to the establishment of the International Conference on Harmonisation (ICH) in 1991. The ICH introduced a series of guidelines covering quality, safety, efficacy, and multidisciplinary topics, collectively referred to as the Q, S, E, and M guidelines. These guidelines provided a unified framework for drug substance and drug product evaluation in terms of quality, safety, and efficacy. Parallel to this, the World Health Organization (WHO) initiated work on pharmaceutical product stability in 1998. The WHO Guidelines on Stability Testing for Well-Established Drug Substances in Conventional Dosage Forms were adopted in 1996 by the WHO Expert Committee on Specifications for Pharmaceutical Preparations after extensive consultation. Later, in 2000, discussions commenced between the ICH Expert Working Group Q1 (Stability) and WHO, aiming to harmonize the number of stability tests and conditions employed globally. These collective efforts laid the foundation for modern stability testing practices, ensuring consistent evaluation of pharmaceutical products worldwide to safeguard patient safety and therapeutic efficacy (Figure 1). [7-8]



Figure 1: Histological background in stability testing developments

3. TYPESOF DRUGSTABILITYSTUDIES

Stability studies are conducted to evaluate the performance of a drug product over extended periods under varying conditions of temperature and humidity. Such studies are particularly crucial when the product is distributed across diverse geographical regions or requires shipping, as environmental variations can significantly affect stability [9-10]. Long-term stability testing involves storing samples under defined conditions and analyzing them at predetermined intervals to monitor any physical, chemical, or microbiological changes. The primary objective of these studies is to establish the shelf-life of the drug product.

As per ICH guidelines, 30°C ± 2°C/65% RH ± 5% RH may be considered an acceptable alternative to the conventional 25°C ± 2°C/60% RH ± 5% RH for the following:
Drug Substance – Storage Conditions (General Case)
Drug Product – Storage Conditions (General Case)

Intermediate stability studies are performed at 30°C ± 2°C/65% RH ± 5% RH to provide supportive data for products intended for long-term storage at 25°C. These conditions help to moderately accelerate the rate of chemical degradation or physical changes without subjecting the product to extreme stress.

Accelerated stability testing is conducted under exaggerated storage conditions to predict the potential degradation pathways and to establish the product's stability profile within a shorter time frame [11-12]. These studies simulate the impact of harsh environmental factors on the drug substance or product and provide preliminary data that can be extrapolated to estimate long-term stability and shelf-life.

In-use stability studies are particularly important for multi-dose drug products that are intended to be administered over an extended period. Such products are repeatedly opened and closed during use, making them susceptible to physical and chemical degradation as well as microbial contamination. The purpose of in-use stability testing is to determine, where applicable, the maximum period during which a multi-dose product can be safely used after the container has been opened, while ensuring that the product continues to meet its quality specifications throughout this period (Table 1). [13-14]

Table 1: Types of Drug Stability Studies

Type of Stability Study	Storage Conditions (ICH Guidelines)	Purpose	Key Features
Long-term stability	25°C ± 2°C / 60% RH ± 5% RH (conventional) 30°C ± 2°C / 65% RH ± 5% RH (alternative)	To establish shelf-life of the drug product under normal storage conditions.	Conducted for extended duration; samples analyzed at predetermined intervals to monitor physical, chemical, and microbiological changes.
Intermediate stability	30°C ± 2°C / 65% RH ± 5% RH	To provide supportive data for long-term storage at 25°C.	Moderately accelerates chemical/physical changes without extreme stress; bridges long-term and accelerated conditions.
Accelerated stability	Exaggerated conditions (e.g., 40°C ± 2°C / 75% RH ± 5% RH)	To predict degradation pathways and estimate stability profile in shorter time.	Simulates harsh environmental impact; data used for extrapolation of long-term shelf-life.
In-use stability	Realistic usage conditions (post-opening of multi-dose container)	To determine safe usage period after opening for multi-dose products.	Assesses susceptibility to degradation and microbial contamination during repeated opening/closing.

4. APPLICATIONOFSTABILITYTESTINGTOPHARMACEUTICALMETHOD

Pharmaceutical products are the one whose stability needed to be check which would otherwise affect the life of people. Hence stability study are included which test those attributes of drug which are susceptible to change during storage and are likely to influence quality, safety and efficacy. The testing should cover the following important attributes. [15-16]

As described earlier, physical, chemical, and microbiological data are generated as a function of time and storage conditions (e.g., temperature and relative humidity). The stability of pharmaceutical product is affected by the potential that is main drug interaction with its excipients; the manufacturing process, the dosage form, and the container/closure system. The

drug product stability is not only affected by above but also changes with time and environmental distribution. Seasonal changes, mode of transportation, and the number of drop- off points are the other variables that should be considered within the pharmaceutical supply chain. Not only physically but also chemically like oxidation, reduction, hydrolysis, or racemization play a vital role. Drug products which require the controlled-temperature storage conditions must be distributed in a manner that ensures that the product quality will not be adversely affected [17-18].

Physical stability

Explain that the formulation is totally unchanged throughout it shelf life and has not suffered any changes in its appearance, organoleptic properties, and other physical properties (like hardness, brittleness, particle size etc in case if it is solid). The drug release nature (rate and mechanism) should not be altered. Different parameters are adapted for checking different stability criteria of different physical properties. Physical stability affect to drug uniformity and release rate hence it is important from safety and efficiency point of view. [19]

Chemical stability

Implies that lack of chemical entity that is incorporated in formulation as the drug. The chemicals already present in formulation as preservative or excipients may also influence or alter the chemical stability of drug content. The Chemical stability of drug is of great importance since it becomes less effective as it undergoes degradation. Also drug decomposition may yield toxic byproducts that are harmful to the patient. [20]

Microbiological stability

Implies itself that the formulation has not suffered from any microbiological attack and is meeting the standards with respect to lack of sterility growth of microorganism. Microbiological instability of a sterile drug product could be hazardous. [21-22]

5. STRATEGIESFORDEVELOPMENTOFSTABILITYINDICATINGMETHOD

Without knowing the stability testing of a drug, the formulation can present a high risk of failure, potentially leading to economic loss and therapeutic inefficacy. Therefore, several systematic steps are followed in the development of stability methods.The structural and physicochemical properties of the active pharmaceutical ingredient (API) play a crucial role in predicting degradation pathways. Information such as pKa, pH, log P, solubility, molecular weight, and λmax is essential for sample preparation techniques. The chemical structure provides insights into the molecular weight and the nature of functional groups (acidic, basic, aromatic, etc.), which are potential active sites for degradation through hydrolysis, oxidation, or thermal stress.Setting up chromatographic conditions is a critical step during initial method development. Factors such as mobile phase parameters (percentage organic solvent, buffer type and concentration, pH, solvent type), operating parameters (flow rate, temperature, gradient range, and gradient time), column characteristics (bonded phase type, length, diameter, and particle size), and detector settings (monitoring wavelength, sample amount) must be optimized. Detector selection depends on the analyte's properties: compounds with UV absorbance can be analyzed using a UV/Vis spectrophotometer, while analytes without UV absorbance may require refractive index detectors. For ionizable analytes, mass spectrometry (MS) is an appropriate choice. Mobile phase solvents for HPLC should possess high solubility for the API, be noncorrosive, of high purity, UV-transparent, low in toxicity, non-flammable, and cost-effective. Reversed-phase chromatography (RPC) is often employed for ionizable compounds, with acidic pH (2.5–3) being common, as it suppresses ionization of weakly acidic analytes, thereby improving retention. Column efficiency is influenced by column length, particle size, and distribution, all of which affect analysis speed and pressure drop. Columns with high surface area provide stronger retention, and selection of high-purity silica-bonded phases (3–5 μm) is recommended, with 3 μm preferred for faster analysis. [23-27]

Sample preparation is another essential aspect of method development. Stability-indicating methods (SIMs) are routinely developed for APIs, often differing from those used in accelerated stability testing. Stress testing, also known as forced degradation, provides valuable information about degradation pathways and potential products that may form during storage, aiding formulation development, manufacturing, and packaging. Force degradation is performed using thermolysis, hydrolysis, oxidation, photolysis, or combinations thereof, with analysis conducted through HPLC detectors. The "dilute and shoot" approach is often suitable for parenteral and simple drug substances, while solid dosage forms such as tablets or capsules usually follow "grind → extract → dilute → filter." [28-32]

Complex formulations such as creams, lotions, or biological samples may require liquid-liquid extraction or solid-phase extraction.Developing a separation method involves ensuring clear resolution of the API peak from degradation products. The choice of solvent depends on solubility, buffer compatibility, UV properties, and safety considerations. Solvents with unsuitable properties such as high viscosity, poor UV transparency, or inappropriate boiling points are avoided. Elution mode is another consideration: isocratic elution employs the same solvent throughout, while gradient elution accelerates the separation of strongly retained components and enhances resolution. Column parameters, including silica or polymer

types, dimensions, and particle/pore size, greatly influence efficiency, selectivity, and elution. Stationary phase chemistry determines whether the column is suitable for normal or reverse-phase chromatography. Column temperature also impacts selectivity, as elevated temperatures typically reduce retention for neutral compounds. Controlled temperature using a column oven ensures reproducibility.Method optimization is achieved through systematic variation of parameters such as mobile phase pH, chromatographic mode, flow rate, column type and temperature, sample concentration, injection volume, solvent choice, and detection wavelength. This ensures robust conditions for stability-indicating assays.Finally, analytical method validation is performed according to ICH guidelines, which require evaluation of accuracy, precision, specificity, detection limit, quantitation limit, linearity, and range. Specificity is determined using known impurities, while precision is assessed by repeatability of assays with multiple samples. Assay ranges typically span 50–110% of the nominal sample concentration. These steps ensure that the developed method is reliable, reproducible, and capable of accurately determining the stability of pharmaceutical formulations (Table 2). [33-36]

Table 2: Strategies for Development of Stability-Indicating Methods

Parameter	Key Considerations	Practical Aspects
API characterization	Structural and physicochemical properties (pKa, pH, log P, solubility, MW, λmax)	Predict degradation pathways (hydrolysis, oxidation, thermal stress); identify functional groups prone to degradation.
Chromatographic conditions	Mobile phase composition, buffer type/concentration, pH, solvent type, gradient range/time	Reverse-phase preferred for ionizable compounds; acidic pH (2.5–3) improves retention; solvent should be UV-transparent, non-toxic, cost-effective.
Column selection	Bonded phase type, column length, diameter, particle size, surface area	High-purity silica phases (3–5 µm); 3 µm preferred for faster analysis; column temperature controlled via oven for reproducibility.
Detector selection	Based on analyte properties	UV/Vis for chromophores; refractive index for non-UV absorbing analytes; MS for ionizable compounds.
Sample preparation	Depends on formulation type	Simple drugs/parenterals: “dilut

6. EMESIS

Vomiting is triggered by stimulation of the emetic centre located in the medulla oblongata, which integrates signals from multiple pathways. Two major relay areas, the chemoreceptor trigger zone (CTZ) situated in the area postrema and the nucleus tractus solitarius (NTS), play a key role in transmitting afferent impulses from the gastrointestinal tract, pharynx, and other visceral organs. The CTZ is particularly sensitive to circulating drugs, hormones, toxins, and mediators since it lies outside the protection of the blood–brain barrier (Figure 2). [37-38]

Chemotherapeutic agents, radiation, and gastrointestinal irritants stimulate enterochromaffin cells to release serotonin (5-HT). This 5-HT acts on 5-HT3 receptors located on extrinsic primary afferent neurons (PAN) of the enteric nervous system (ENS). These neurons, in turn, transmit signals via vagal and spinal visceral afferents to the NTS and CTZ. Excessive serotonin may also enter the systemic circulation, reaching the CTZ through the vascular route. Inflammatory mediators can additionally induce serotonin release from platelets. However, serotonin is not the sole mediator of emetic signaling—other neuropeptides, such as substance P, also play a significant role. [39]

The CTZ and NTS contain a wide range of receptor types, including histamine H1, dopamine D2, serotonin 5-HT3, muscarinic cholinergic, neurokinin NK1 (activated by substance P), cannabinoid CB1, and opioid µ receptors. These receptors act as key targets for various antiemetic agents.

The vestibular apparatus contributes to vomiting when balance or motion is disturbed, or under the influence of ototoxic drugs. Signals from the vestibular system are relayed through the cerebellum and involve H1 and muscarinic receptors. In addition, unpleasant sensory inputs such as foul odours, disturbing visuals, intense pain, fear, or recollection of previous emetic experiences can induce nausea and vomiting via higher cortical centres. [40]

Physiologically, nausea is associated with decreased gastric tone and reduced peristaltic activity. During the vomiting reflex, the fundus and body of the stomach, esophageal sphincter, and esophagus relax, while the duodenum and pyloric region contract in a retrograde manner. Contraction of the diaphragm and abdominal muscles then exerts pressure on the stomach, leading to expulsion of its contents through the mouth. This reflex response is often enhanced under conditions that impair gastric emptying. [41]



Figure 2: Vomiting reflex pathways

Emetics are drugs that induce vomiting and are generally employed when a harmful substance, such as a poison, has been ingested. Agents like apomorphine act directly on the chemoreceptor trigger zone (CTZ), while ipecacuanha acts both reflexively and on the CTZ. In emergency situations, vomiting can also be induced by using powdered mustard suspension or strong salt solutions, which act reflexively by irritating the gastric mucosa. In contrast, antiemetics are drugs used to prevent or suppress vomiting. Different classes of antiemetics act through various mechanisms. Anticholinergics such as hyoscine and dicyclomine are useful in motion sickness. H1 antihistamines like promethazine, diphenhydramine, doxylamine, dimenhydrinate, meclozine, and cinnarizine are effective in controlling nausea of vestibular origin. Neuroleptics, including chlorpromazine, triflupromazine, prochlorperazine, and haloperidol, act as dopamine D2 receptor antagonists. Prokinetic agents such as metoclopramide, domperidone, cisapride, mosapride, and itopride enhance gastric emptying and possess antiemetic effects. Another important group comprises 5-HT3 receptor antagonists, including ondansetron, granisetron, palonosetron, and ramosetron, which are highly effective against chemotherapy-induced nausea and vomiting. NK1 receptor antagonists, such as aprepitant and fosaprepitant, block the action of substance P and provide additional protection, particularly in combination regimens. Finally, several drugs are used as adjuvant antiemetics, including dexamethasone, benzodiazepines, and cannabinoids like dronabinol and nabilone, which enhance the efficacy of primary antiemetic therapy in resistant cases. [41]

7. REGULATORY EVOLUTION AND DIGITAL INTEGRATION

In recent years, regulatory frameworks for stability studies have been evolving beyond conventional analytical validation approaches. Global agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are increasingly encouraging the integration of digital tools and advanced technologies in analytical method development and validation. Concepts such as digital validation platforms, artificial intelligence (AI)-assisted stability prediction, and real-time release testing (RTRT) are gaining recognition as part of modern regulatory expectations. The application of machine learning algorithms trained on historical stability data offers promising avenues for forecasting degradation patterns, predicting shelf life, and identifying potential impurities even before they are experimentally observed. Such predictive analytics can reduce the reliance on prolonged stability testing, thereby accelerating drug

development timelines. Furthermore, regulatory authorities are promoting the incorporation of data integrity principles, electronic laboratory notebooks (ELNs), and digital audit trails to strengthen compliance and transparency. Collectively, these advancements indicate a paradigm shift towards digitally driven, predictive, and adaptive regulatory frameworks, which will significantly influence the future landscape of stability-indicating methods for antiemetic drugs. [38-41]

8. CONCLUSION

Stability studies are designed to distinguish the active pharmaceutical ingredient from its degradation products formed under defined storage conditions. They also provide insight into the possible degradation pathways, whether physical, chemical, or microbiological. By subjecting drugs to varied conditions of temperature and relative humidity, different stability profiles can be identified, allowing the characterization of degradation products. Forced degradation studies hold particular importance in the development of stability-indicating analytical methods, as they help in understanding the intrinsic stability of a drug molecule. Chromatographic techniques, especially HPLC, play a central role in impurity detection and degradation profiling. This review highlights the current regulatory requirements and guidelines governing forced degradation experiments, emphasizing their application in the development of stability-indicating methods. Several strategies have been adopted for the quantitative evaluation of antiemetic drugs, and this study aims to provide a comprehensive overview of the literature on stability-indicating HPLC and RP-HPLC methodologies for their development and validation.

REFERENCES

[1] Huynh-Ba K. Handbook of stability testing in pharmaceutical development: Regulations, methodologies and best practices. New York: Springer; 2008. p.1–19.
[2] John SC. Fundamentals of stability testing. Int J Cosmet Sci. 2007;7:291–303.
[3] Ajay M, Vipin K, Renu, Sunil, Tarun K. World Health Organization's guidelines for stability testing of pharmaceutical products. J Chem Pharm Res. 2011;3:892–8.
[4] Pranshu T, Bhanu B. WHO role and guidelines in stability study of pharmaceuticals: A regulatory perspective. Int J Res Pharm Biomed Sci. 2012;3:1379–85.
[5] Hogerzeil HV, Battersby A, Srdanovic V, Stjernstrom NE. Stability of essential drugs during shipment to the tropics. BMJ. 1992 Jan 25;304:210–2.
[6] Kenneth CW, Paul G, Zhen D. A generalized relation for solid-state drug stability as a function of excipient dilution: Temperature-independent behavior. J Pharm Sci. 2012;101:4170–7.
[7] Singh S, Bakshi M. Development of validated stability-indicating assay methods—critical review. J Pharm Biomed Anal. 2002;28:1011–40.
[8] Wolfgang G. A rational approach to stability testing and analytical development for NCE, drug substance and drug product: Marketed product stability testing. In: Drug stability principles and practices. New York: Marcel Dekker; 2000. p.416–8.
[9] Sumic Y, Valentino S. Stability of drugs and dosage forms. Dordrecht: Kluwer Academic Publishers; 2002. p.151–84.
[10] Monika B, Saranjit S. Development of validated stability-indicating assay method—critical review. J Pharm Biomed Anal. 2002;28:1011–40.
[11] Amruth Kr N, ThiruvengadaRajan VS, MadhusudhanaChetty C. A review on stability studies—an overview. Int J Rev Life Sci. 2011;4:106–11.
[12] Sanjay B, Dinesh S, Neha S. Stability testing of pharmaceutical products. J Appl Pharm Sci. 2012;2:129–38.
[13] Patel RM, Patel PM, Patel NM. Stability indicating HPLC method development – a review. Int Res J Pharm. 2011;2:79–87.
[14] Snyder LR, Kirkland JJ. Introduction to modern liquid chromatography. 2nd ed. New York: John Wiley & Sons; 1979. p.127–60, 168–230, 247–9.
[15] George N. Forced degradation as an integral part of HPLC stability indicating method development. Drug Deliv Technol. 2010;10:5.
[16] Mehta AC. Strategies for stability studies on hospital pharmaceutical preparations. Int J Pharm Pharmacol. 2012;2:49–52.
[17] ICH. Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products (ICH Q5C). Geneva: International Council for Harmonisation; July 1996.
[18] Kats M. Forced Degradation Studies: Regulatory Considerations and Implementation. BioPharm International. 2005 Jul;18(1):1–7.
[19] Rina HG, Kinjal ND. Stability study: Regulatory requirement. Int J Adv Pharm Anal. 2012;2:3.
[20] Dan WR, Kelvin LF. Available guidance and best practices for conducting forced degradation studies. Pharm Technol. 2002;48–57.
[21] Tripathi KD. Essentials of medical pharmacology. 7th ed. New Delhi: Jaypee Brothers Medical Publishers; 2013. p.661–6.

[22] Shende M, Agrawal S. Simultaneous estimation of mefenamic acid and hyoscine-n-butyl bromide by novel RP-HPLC method in bulk and pharmaceutical dosage form. Indo Am J Pharm Sci. 2017;4(10):3608–17.
[23] Shaalan RA, Haggag RS, Belal SF, Agami M. Simultaneous determination of hyoscine, ketoprofen and ibuprofen in pharmaceutical formulations by RP-HPLC–DAD. 2013.
[24] Tandel JN, Patel J, Patel RR, Shah SK. Estimation of hyoscinebutylbromide and mefenamic acid by RP-HPLC method development and accelerated stability study in pure and combined dosage form. Eurasian J Anal Chem. 2018;13:35.
[25] Mohamed M, Ali NW, Gamal M. LC-MS as a stability-indicating method for analysis of hyoscine N-butyl bromide under stress degradation conditions with identification of degradation products. Future J Pharm Sci. 2013;1:1.
[26] Ali NW, Gamal M, Abdelkawy M. Simultaneous determination of hyoscine N-butyl bromide and paracetamol in their binary mixture by RP-HPLC method. Arab J Chem. 2017;10:S1868–74.
[27] Takale N, Kaliyaperumal N, Krishnan G, Mannathusamy, Govindasamy RR. Stability indicating RP-HPLC method development for related substances of antihistamine promethazine hydrochloride and its validation study. Orient J Chem. 2020;36(5).
[28] Ajay Kumar, Mishra R, Mishra B. Validation of RP-HPLC based stability indicating assay for promethazine hydrochloride. Int J Pharm Pract Pharm Sci. 2020;2(1).
[29] Gao S, Zhou X, Lang L, Liu H, Li J, Li H, et al. Simultaneous determination of schisandrin and promethazine with its metabolite in rat plasma by HPLC-MS/MS and its application to a pharmacokinetic study. Int J Anal Chem. 2019;2019:1–8.
[30] Kakadiya J, et al. Development and validation of RP-HPLC method for simultaneous estimation of promethazine hydrochloride and paracetamol in combined liquid formulation. Asian J Res Biol Pharm Sci. 2014;2(1):11–26.
[31] Kumar BP, Vidyadhara S, Murthy TEGK, Sasidhar RLC, Krishna VS. Development and validation of RP-HPLC method for simultaneous estimation of doxylamine succinate and pyridoxine hydrochloride in bulk and pharmaceutical dosage forms. Eurasian J Anal Chem. 2017;12(5):459–68.
[32] Giriraj P, Sivakkumar T. Development and validation of a rapid chemometrics assisted RP-HPLC with PDA detection method for simultaneous estimation of pyridoxine HCl and doxylamine succinate in bulk and pharmaceutical dosage form. Chromatogr Res Int. 2014;2014:1–2.
[33] Ravichandran S, et al. RP-HPLC method development and validation for the doxylamine succinate and pyridoxine HCl in its pure and pharmaceutical tablet dosage form. 2018;8:35–43.
[34] Richards P. A new RP-HPLC method development and validation for simultaneous estimation of pyridoxine hydrochloride and doxylamine succinate in bulk drug and pharmaceutical tablet dosage form. IOSR J Pharm Biol Sci. 2017;12(5):74–9.
[35] Varasala D, Konidala S. Stability-indicating RP-HPLC method development and validation for simultaneous determination of doxylamine succinate and dextromethorphan hydrobromide in pharmaceutical dosage forms. Der Pharm Lett. 2015;7(2):112–8.
[36] Donda ST, Baviskar VB, Bari SB, Deshmukh PK, Deore DS, Girase NM, et al. Development and validation of RP-HPLC method for the simultaneous estimation of tramadol hydrochloride and dicyclomine in bulk and pharmaceutical formulation. J Chil Chem Soc. 2016;61(2):2852–5.
[37] Rao N, Desai A. RP-HPLC method development and validation for estimation of dicyclomine hydrochloride in its bulk and drops form. Res J Pharm Technol. 2021;14(2):605–9.
[38] Baokar S, Sugandha M, Nisharni R. Development and validation of RP-HPLC method for simultaneous determination of mefenamic acid. 2014;1–2.
[39] Chaitanya V, Bhaskar D, Kamarpu SK. Method development and validation of RP-HPLC method for simultaneous estimation of dicyclomine hydrochloride and diclofenac potassium in tablet dosage form. 2013;3(4):255–64.
[40] Shah DA, Rana JP, Chhalotiya UK, Baldaniya SL, Bhatt KK. Development and validation of a liquid chromatographic method for estimation of dicyclomine hydrochloride, mefenamic acid, and paracetamol. 2014.
[41] Giriraj P, Sivakkumar T. Development and validation of a rapid chemometrics assisted RP-HPLC with PDA detection method for the simultaneous estimation of pyridoxine HCl and doxylamine succinate in bulk and pharmaceutical dosage form. Chromatogr Res Int. 2014; 2014.